PVCT - PROVECTUS BIOPHARMACEUTICALS, INC.

0.0972
-0.003   -2.572%

Share volume: 397,895
Last Updated: 04-04-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$0.10
0.00
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 0%
Dept financing 50%
Liquidity 3%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.51%
1 Month
-5.63%
3 Months
-13.29%
6 Months
-19.27%
1 Year
-19.27%
2 Year
-19.27%
Key data
Stock price
$0.10
P/E Ratio 
0.00
DAY RANGE
$0.09 - $0.10
EPS 
-$0.01
52 WEEK RANGE
$0.08 - $0.12
52 WEEK CHANGE
-$19.27
MARKET CAP 
50.419 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$191,482
AVERAGE 30 VOLUME 
$333,013
Company detail
CEO: Bruce Horowitz
Region: US
Website: provectusbio.com
Employees: 4
IPO year: 2013
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Provectus Biopharmaceuticals, Inc. engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumors, such as head and neck, breast, testicular, and colorectal cancers.

Recent news
loading